Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | AHCY | P23526 | 7/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | PI4KA | P42356 | 2/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ADCY5 | O95622 | 2/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eritadenine SCHEMBL308656 | 1.00 | ALDH1A1 (0.76) | ALDH1A1AHCYADORA2AADORA1EGFR | |
| Eritadenine SCHEMBL27715791 | 1.00 | ALDH1A1 (0.76) | ALDH1A1AHCYADORA2AADORA1EGFR | |
| SCHEMBL2049963 | 0.86 | ALDH1A1 (1.00) | ALDH1A1AHCYADORA2AADORA1EGFR | |
| SCHEMBL2049962 | 0.86 | ALDH1A1 (1.00) | ALDH1A1AHCYADORA2AADORA1EGFR | |
| SCHEMBL2049965 | 0.86 | ALDH1A1 (1.00) | ALDH1A1AHCYADORA2AADORA1EGFR | |
| SCHEMBL2270408 | 0.83 | ALDH1A1 (0.75) | ALDH1A1AHCYADORA2AADORA1EGFR | |
| SCHEMBL10683911 | 0.83 | ALDH1A1 (0.75) | ALDH1A1AHCYADORA2AADORA1EGFR | |
| SCHEMBL6532875 | 0.82 | ALDH1A1 (0.73) | ALDH1A1AHCYADORA2AADORA1EGFR | |
| SCHEMBL11474105 | 0.82 | AHCY (0.76) | ALDH1A1AHCYADORA2AADORA1PI4KA | |
| SCHEMBL16603993 | 0.81 | AHCY (0.85) | ALDH1A1AHCYADORA2AADORA1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240075017-A1 | TREATMENT OF CORONAVIRUS INFECTIONS USING SAM CYCLE INHIBITORS | UNIV MUENCHEN TECH (DE) | 2024-03-07 | — | — | US | claimed |
| EP-4304573-A1 | TREATMENT OF CORONAVIRUS INFECTIONS USING SAM CYCLE INHIBITORS | Technische Universität München (DE) | 2024-01-17 | — | — | EP | claimed |
| WO-2022189379-A1 | TREATMENT OF CORONAVIRUS INFECTIONS USING SAM CYCLE INHIBITORS | Technische Universität München (DE) | 2022-09-15 | — | — | WO | claimed |
| US-20150057243-A1 | Compositions and Methods for the Inhibition of Methyltransferases | NORTHERN UNIVERSITY (US) | 2015-02-26 | — | — | US | claimed |
| WO-2013151975-A1 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF METHYLTRANSFERASES | NORTHEASTERN UNIVERSITY (US) | 2013-10-10 | — | — | WO | claimed |
| CN-102803474-A | Beta-cell replication promoting compounds and methods of their use | HARVARD COLLEGE | 2012-11-28 | — | — | CN | claimed |
| US-20090214511-A1 | DIGESTIBLE COMPOSITIONS OF INULIN FOR MANAGING BLOOD GLUCOSE LEVELS | TRAN TRUNG HONG | 2009-08-27 | — | — | US | claimed |
| WO-2025104184-A1 | METHOD OF GENERATING HAEMATOPOIETIC CELLS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-05-22 | — | — | WO | disclosed |
| US-20240075017-A1 | TREATMENT OF CORONAVIRUS INFECTIONS USING SAM CYCLE INHIBITORS | UNIV MUENCHEN TECH (DE) | 2024-03-07 | — | — | US | disclosed |
| EP-4304573-A1 | TREATMENT OF CORONAVIRUS INFECTIONS USING SAM CYCLE INHIBITORS | Technische Universität München (DE) | 2024-01-17 | — | — | EP | disclosed |
| US-20230302003-A1 | COMPOSITIONS AND METHODS FOR TREATING A CORONAVIRUS INFECTION | ANTIRNA INCORPORATED | 2023-09-28 | — | — | US | disclosed |
| US-20230014430-A1 | Methods and Compositions for Generating Functionally Mature Beta Cells and Uses Thereof | WASHINGTON UNIVERSITY (US) | 2023-01-19 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| WO-1996020010-A1 | COMBINATION FOR REDUCING ANTIMICROBIAL RESISTANCE USING A METHYLATION INHIBITOR IN COMBINATION WITH AN ANTIBIOTIC | ORIDIGM CORPORATION (US) | 1996-07-04 | — | — | WO | disclosed |
| EP-0205826-B1 | PHOSPHONYLMETHOXYALKYL ADENINES FOR THE TREATMENT OF VIRUS DISEASES | Stichting REGA V.Z.W. (BE) | 1992-03-18 | — | — | EP | disclosed |
| US-5073641-A | PRODRUG DERIVATIVES OF CARBOXYLIC ACID DRUGS | BUNDGAARD HANS (DK) | 1991-12-17 | — | — | US | disclosed |
| EP-0278977-A1 | PRODRUG DERIVATIVES OF CARBOXYLIC ACID DRUGS. | BUNDGAARD HANS (DK) | 1988-08-24 | — | — | EP | disclosed |
| WO-1988001615-A1 | PRODRUG DERIVATIVES OF CARBOXYLIC ACID DRUGS | BUNDGAARD HANS (DK) | 1988-03-10 | — | — | WO | disclosed |
| US-4724233-A | VIRICIDES | STICHTING REGA VZW (BE) | 1988-02-09 | — | — | US | disclosed |
| EP-0205826-A2 | Phosphonylmethoxyalkyl adenines for the treatment of virus diseases | Stichting REGA V.Z.W. (BE) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302003-A1 | COMPOSITIONS AND METHODS FOR TREATING A CORONAVIRUS INFECTION | AHCY, AHCYL1, BHMT | ALDH1A1 718/4885AHCY 1/4885ADORA2A 322/4885 |
| US-20150057243-A1 | Compositions and Methods for the Inhibition of Methyltransferases | RNMT, EMG1, NSUN2 | ALDH1A1 3025/4885AHCY 33/4885ADORA2A 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.